Does Finasteride Cause Cancer? What the Research Shows

Finasteride does not cause cancer. The largest and longest-running trial on this question found the opposite: men who took finasteride were roughly 25% less likely to be diagnosed with prostate cancer than men on placebo. The story got complicated early on by a signal suggesting finasteride might increase the risk of aggressive prostate tumors, a finding that sparked years of debate and a black-box label warning. More recent analyses have largely resolved that controversy, and the drug’s relationship to other cancers is worth understanding on its own terms.

What the Prostate Cancer Prevention Trial Found

The Prostate Cancer Prevention Trial, known as the PCPT, remains the definitive study on finasteride and cancer risk. It enrolled nearly 19,000 men aged 55 and older with no prior prostate cancer and randomized them to either finasteride (5 mg daily) or placebo for seven years. The results were striking: prostate cancer was detected in about 18% of men in the finasteride group compared with about 24% in the placebo group, a reduction of roughly one quarter.¹ That finding alone should have settled the question. But a secondary finding clouded the picture: among the cancers that were detected, a higher proportion of tumors in the finasteride group received high Gleason grades, a pathology scoring system indicating more aggressive disease. That observation set off alarm bells and led the FDA to add a warning to finasteride’s label.

Long-term follow-up data eventually became available. After roughly 18 years of observation, the overall risk reduction held steady, with prostate cancer diagnosed in about 10.5% of the finasteride group compared with about 15% of the placebo group.² And critically, there was no difference in overall survival between the two groups. Men who took finasteride were not more likely to die of prostate cancer or anything else over that period. The cancer prevention benefit was real, and the feared mortality cost from aggressive tumors never materialized.

The High-Grade Cancer Scare and Why It Faded

The initial PCPT results showed that high-grade prostate cancers (Gleason 7 and above) appeared more often in the finasteride arm. This was alarming on its face, but researchers had a plausible explanation almost immediately: finasteride shrinks the prostate. A smaller gland means that a standard biopsy needle samples a larger proportion of the tissue. Cancers that might be missed in a bigger prostate become easier to detect in a smaller one. This is a detection bias, not a biological effect of the drug.

A detailed modeling study of the PCPT data investigated exactly this. After adjusting for the increased biopsy sampling density that comes with a smaller prostate, the researchers concluded that the sampling bias alone could account for the apparent excess of high-grade cancers in the finasteride group.³ In other words, finasteride did not create more aggressive cancers. It just made them easier to find.

There is also a grading artifact to consider. Finasteride, like other forms of androgen deprivation, induces changes in the appearance of prostate cells: the cytoplasm clears, nuclei shrink, and chromatin condenses. These changes can make cancer cells look architecturally worse under a microscope even though their nuclear features are actually less aggressive, creating the possibility that pathologists assigned higher Gleason grades to cancers that were not truly more dangerous.⁴ Interestingly, a separate study looking specifically at needle biopsies from finasteride-treated patients found no significant histologic differences between finasteride and placebo in either benign tissue or cancer tissue, suggesting the grading confusion may apply more to heavily treated cases than to the typical BPH patient.⁵

Taken together, the detection bias from prostate shrinkage and the potential for grading artifacts offer two independent explanations for the high-grade signal. Neither implies that finasteride makes cancer worse. The long-term survival data, showing no mortality difference, confirms that the feared outcome never arrived.

What About Lower Doses Used for Hair Loss

Most of the cancer research on finasteride comes from studies using the 5 mg dose prescribed for benign prostate enlargement. Men taking finasteride for hair loss typically use 1 mg per day, and they tend to be younger, so the question of whether the same risk-reduction findings apply to them has lingered. A recent propensity-matched observational study addressed this directly, looking at men with hair loss taking lower-dose finasteride over several years. At five years, finasteride use was associated with about half the risk of a prostate cancer diagnosis compared with matched non-users, and the absolute rate of prostate cancer remained very low in both groups.⁶

This makes pharmacological sense. Finasteride blocks the enzyme that converts testosterone into DHT, which is the primary androgen driving prostate cell growth.⁷ Even at 1 mg, finasteride substantially suppresses serum DHT. The prostate-protective signal persisting at the lower dose is consistent with the drug’s mechanism. For the typical young man taking finasteride for thinning hair, there is no evidence of increased cancer risk and at least preliminary evidence of reduced prostate cancer risk over time.

Male Breast Cancer

Male breast cancer is rare, affecting roughly 1 in 100,000 men per year. Because finasteride shifts the testosterone-to-estrogen balance (by blocking DHT production, relatively more testosterone is available for conversion to estrogen), researchers have investigated whether the drug might raise breast cancer risk in men. The evidence here is genuinely mixed, and worth understanding in detail because it occasionally surfaces in alarming headlines.

A Nordic cohort study covering Denmark, Finland, Sweden, and Norway found that finasteride users had a modestly elevated rate of male breast cancer compared with non-users. The increase was most pronounced in men under 70, where the rate was several times higher among users.⁸ A UK case-control study found a similar pattern among heavy users: men who had received 25 to 50 prescriptions over five years had a statistically significant increased risk compared to non-users.⁹

However, a large case-control study drawing individual-level registry data from Denmark, Finland, and Sweden found no significant association between finasteride use and male breast cancer after adjusting for confounders. In fact, the group with the greatest cumulative exposure to finasteride had the lowest odds of breast cancer, which runs directly against a dose-response relationship.¹⁰

How do you reconcile these findings? The cohort studies show a signal, but cohort designs in rare diseases are vulnerable to confounders that are hard to fully adjust away. Men who take finasteride already have a reason to visit a urologist regularly, which means more clinical contact and more opportunity to detect an uncommon cancer. The case-control study, which matched cases and controls more carefully and found no association, offers a useful counterpoint. The honest read is that a small increase in male breast cancer risk cannot be completely ruled out with prolonged high-dose use, but the absolute risk remains extremely small even in the studies that found an association. This is not a reason most men would stop the drug, but it is worth knowing about for anyone on long-term therapy.

Bladder Cancer

Because DHT influences the biology of the bladder as well as the prostate, researchers have asked whether finasteride affects bladder cancer risk. A large multiethnic cohort study found that finasteride users had a substantially lower rate of bladder cancer: about 1.5% versus 2.1% among non-users, corresponding to roughly a one-third reduction in risk. The protective signal was strongest in White and Hispanic men; no association was seen in Black men.¹¹

A secondary analysis of a different trial, however, found no difference in bladder cancer incidence between finasteride users and non-users, though that study was considerably smaller and had fewer bladder cancer events overall.¹² The discrepancy may come down to statistical power: bladder cancer is uncommon enough that small studies struggle to detect a difference. The larger study’s finding is more robust, but it would be premature to call finasteride a bladder cancer preventive. What you can say is there is no evidence that it increases bladder cancer risk, and there is at least a plausible signal that it may lower it.

Melanoma and Skin Cancer

An unexpected research thread has explored whether finasteride affects melanoma risk. A population-level analysis found that use of finasteride or dutasteride may reduce melanoma risk.¹³ The mechanism is not fully mapped, but laboratory work offers a plausible pathway: finasteride appears to inhibit melanin production in melanocyte cells by downregulating the MC1R receptor and several downstream enzymes involved in pigment synthesis. In cell cultures, finasteride decreased melanin levels in both normal melanocytes and melanoma cells without killing the cells outright.¹⁴

This is still early-stage work. Cell culture findings do not always translate to clinical outcomes, and the epidemiological evidence linking finasteride to reduced melanoma risk is observational. But the direction of the evidence is consistently away from harm: no study has linked finasteride to increased skin cancer risk, and there are scattered signals of a protective effect.

How Finasteride Changes PSA Screening

If you take finasteride and undergo PSA testing for prostate cancer screening, there is a practical wrinkle you need to know about. Finasteride lowers PSA levels, which makes sense given that it shrinks the prostate and reduces the amount of tissue producing PSA. But this means your raw PSA number can be misleadingly low. Data from the PCPT showed that after one year on finasteride, PSA levels roughly halved, and the adjustment factor needed to restore the reading to its “true” range continued increasing over time, reaching about 2.5 after seven years.¹⁵

In practical terms, if you have been on finasteride for a few years and your PSA comes back at, say, 2.0 ng/mL, the “corrected” value may be closer to 5.0. Your doctor should be applying this correction, but not all providers are aware of the need for a time-varying adjustment factor. If you are taking finasteride at any dose and your doctor orders a PSA test, make sure they know about the drug. A falsely reassuring PSA result could delay a cancer diagnosis that the drug ironically makes less likely in the first place.

Finasteride Versus Dutasteride

Dutasteride is the other major 5-alpha-reductase inhibitor, and it blocks both Type 1 and Type 2 forms of the enzyme rather than just Type 2 as finasteride does. A natural question is whether one carries more or less cancer risk than the other. A pooled analysis of 15 real-world databases compared the two drugs head-to-head and found no significant difference in prostate cancer risk between finasteride and dutasteride users.¹⁶ Dutasteride has its own large prevention trial (the REDUCE trial, not among the sources here) that showed similar prostate cancer risk reductions. For anyone choosing between the two drugs, cancer risk does not appear to be a distinguishing factor.

Do Genetics Change the Picture

Researchers have looked for genetic markers that might predict who benefits most or least from finasteride’s cancer-preventive effect. One focus has been the androgen receptor gene, which contains a repeating DNA segment (the CAG repeat) that varies in length between individuals. Longer repeats generally mean a less active receptor. An analysis within the PCPT found no significant association between CAG repeat length and prostate cancer risk, whether looking at the finasteride arm, the placebo arm, or both groups combined, and the finding held for both low-grade and high-grade cancers.¹⁷ This is one of those cases where a plausible biological hypothesis (that men with shorter, more active androgen receptors might respond differently to DHT suppression) simply did not hold up in the data. For now, there is no validated genetic test that would change whether finasteride is appropriate for a given individual with respect to cancer risk.

Why the Cancer Scare Persists

Given the weight of the evidence, you might wonder why anxiety about finasteride and cancer lingers, especially in online communities where the drug is discussed mainly for hair loss. Several factors feed the perception. The FDA’s label warning about high-grade prostate cancer, added after the original PCPT results, was never removed even as subsequent analyses pointed to detection bias as the explanation. Label warnings tend to outlast the evidence that prompted them. Physicians who prescribe finasteride for BPH are usually aware of the nuance, but dermatologists prescribing it for hair loss may not discuss prostate cancer risk at all, which leaves patients to discover the label language on their own without context.

There is also a cognitive asymmetry at work. A drug that “causes cancer” is a vivid, frightening story. A drug that “reduces cancer risk by a quarter but was once thought to increase aggressive tumors due to a biopsy artifact that later analyses attributed to detection bias” is not. The latter is the accurate version, but it does not compress neatly into a headline or a Reddit thread title. For men weighing the decision to start finasteride, the most useful framing is this: the largest and longest trial on the subject shows a clear reduction in prostate cancer incidence, no increase in mortality, and a high-grade signal that has been largely accounted for by artifacts of detection and grading. A possible small increase in male breast cancer risk has been reported in some but not all studies, with the absolute risk remaining very low. No other cancer type shows evidence of increased risk with finasteride use, and there are preliminary signals of reduced risk for bladder cancer and melanoma.